StreetInsider.com News Articles

Delcath Systems to present at ESMO Congress 2026 in Madrid

Mon, 19 Oct 2026 16:01:55 -0400

Delcath Systems, Inc. (Nasdaq: DCTH) announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23–27 in Madrid, Spain, according to a company press release.

On October 24, the company will present a trial-in-progress poster for its DELUMA study, a randomized Phase II trial evaluating melphalan hepatic delivery system induction followed by standard therapy versus standard therapy alone in patients with liver-dominant metastatic breast cancer. The presentation will be led by Heather McArthur, MD, MPH, of UT Southwestern Medical Center.

A "Meet the Investigators" session is also scheduled for October 24,

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Mon, 19 Oct 2026 16:01:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The Company also highlighted the publication of an independent, investigator-led analysis of percutaneous hepatic perfusion (PHP) with melphalan using the CHEMOSAT® Hepatic Delivery System in patients with liver-dominant metastatic uveal melanoma (mUM).

ESMO Congress 2026 Presentation Details

Company Sponsored Trial-in-Progress Poster Presentation
Title: DELUMA: An Open-Label, Randomized Phase

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Mon, 19 Oct 2026 16:01:00 -0400

ESMO Congress 2026 Presentation Details

Company Sponsored Trial-in-Progress Poster Presentation
Title: DELUMA: An Open-Label, Randomized Phase

Form SCHEDULE 13D/A DELCATH SYSTEMS, INC. Filed by: Rosalind Advisors, Inc.

Mon, 19 Oct 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20261019/27203590.html

Form 4 DELCATH SYSTEMS, INC. For: Oct 13 Filed by: Aharon Gil

Wed, 14 Oct 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20261014/27186707.html

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 11 Sep 2026 16:01:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.

The grants, in the form of Restricted Stock Units (RSUs), totaled 34,000 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The RSUs were granted on September 1,

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 11 Sep 2026 16:01:00 -0400

Form S-8 DELCATH SYSTEMS, INC.

Fri, 14 Aug 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260814/26925385.html

Form S-8 DELCATH SYSTEMS, INC.

Fri, 14 Aug 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260814/26925385.html

Form 8-K DELCATH SYSTEMS, INC. For: Aug 12

Fri, 14 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924963.html

Form 8-K DELCATH SYSTEMS, INC. For: Aug 12

Fri, 14 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924963.html

Form 10-Q DELCATH SYSTEMS, INC. For: Jun 30

Thu, 06 Aug 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26880519.html

Form 10-Q DELCATH SYSTEMS, INC. For: Jun 30

Thu, 06 Aug 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26880519.html

Delcath Systems (DCTH) Tops Q2 EPS by 17c

Thu, 06 Aug 2026 08:16:21 -0400

Delcath Systems (NASDAQ: DCTH) reported Q2 EPS of $0.07, $0.17 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.6 million.

For earnings history and earnings-related data on Delcath Systems (DCTH) click here.

Form 8-K DELCATH SYSTEMS, INC. For: Aug 06

Thu, 06 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26879456.html

Form 8-K DELCATH SYSTEMS, INC. For: Aug 06

Thu, 06 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26879456.html

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

Thu, 06 Aug 2026 08:01:00 -0400